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This article refers to ‘Clinical features, predictors and
long-termprognosis of pacing induced cardiomyopathy’ by
S.W. Cho et al., published in this issue on pages 643–651.
The history of permanent cardiac pacing began in 1958 with the
pioneering experiences of Senning and Elmqvist who performed
the first implant on a 43-year-old patient, Arne Larsson, on 8 Octo-
ber 1958.1 Since then, millions of patients have been implanted
with a pacemaker, which is considered a life-saving treatment with
an extremely favourable risk–benefit and cost–benefit profile.2
The conventional technique for implanting a cardiac pacemaker
includes the placement of the ventricular lead at the right ven-
tricular (RV) apex, even though this results in a non-physiological
ventricular activation which may cause left ventricular (LV) dyssyn-
chrony, more frequently in the presence of a depressed LV ejec-
tion fraction (LVEF) at baseline and enlarged LV volumes.3 The
percentage of patients in whom RV apical pacing results in an LV
systolic dyssynchrony detectable with echocardiographic methods
has been reported to be around 50%,4 but it is noteworthy that
also diastolic mechanical dyssynchrony is becoming a subject of
investigation and research in the complex field of heart failure
pathophysiology.5,6
The concept of ‘pacing-induced’ cardiomyopathy (CMP) has
recently been applied to describe the condition characterized
by LV dilatation and hypokinesia, often with symptoms of heart
failure, associated with a high burden of RV pacing. However,
pacing-induced CMP has not been specifically included in classifica-
tion schemes of cardiomyopathies, nor has its definition been fully
established.7 Nevertheless, this condition has been reported in the
literature with variable definitions and with variable frequencies of
occurrence, according to the type of study, methods of assessment
and length of follow-up. In a general view of the literature, a pat-
tern of CMP has been reported to occur in patients treated with
permanent cardiac pacing between 9% at 1 year8 and around 20%
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.. at 3–5 years9,10 of observation. However, the appearance of this
form of CMP does not seem to markedly increase with a longer
follow-up, since a study on patients treated with RV pacing for
> 15 years, with no previous evidence of LV dysfunction, reported
a prevalence of 15.4% after more than 30 years of pacing.11 Since
this type of CMP occurs only in a minority of the patients, the
critical question is to identify what factors predispose or facilitate
its occurrence and modulate its development.
In the present issue of the Journal, Cho et al.12 report on clinical
features and predictors of the occurrence of pacing-induced CMP,
on the basis of the analysis of around 1400 patients implanted with
a pacemaker in a single centre in South Korea. In the study by Cho
et al., pacing-induced CMP was defined as new-onset LV systolic
dysfunction with LVEF < 50%, with either a > 10% decrease in LVEF
as compared to previous evaluations or new-onset regional wall
motion abnormality unrelated to known disease. The occurrence
of this form of CMP was observed during follow-up in 14.1% of
patients after a median of 3.5 years following pacemaker implant,
with a mean decrease in LVEF from 60% to 40%.12 Around 47% of
patients with pacing-induced CMP had admissions for heart failure,
and cardiac death was significantly increased in comparison with
patients without this form of CMP. In the series by Cho et al.,
which specifically excluded patients with depressed LVEF before
pacemaker implant, the independent predictors of pacing-induced
CMP were a left bundle branch block at baseline, wide paced QRS
interval (>155ms) and a higher percentage of ventricular pacing
(≥ 86%), with a 16-fold increase in the risk of CMP when all three
factors were present.12
According to the literature, patients with pre-existing LV
dysfunction, even if moderate (LVEF 41–55%), may present a
higher rate of LVEF worsening with appearance of a pattern of
CMP.13 However, individual factors appear to play a major role in
modulating the changes in LV function observed at long term in
patients implanted with a pacemaker, with either the possibility
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Figure 1 Factors involved in the complex pathophysiology of pacing-induced or pacing-associated cardiomyopathy, with variable influence in
conditioning, modulating or causing the onset of left ventricular (LV) dysfunction with or without overt heart failure. mod., moderate; RV, right
ventricular.
of worsening or, less frequently, of improvement of a mildly
depressed LV function.13 Indeed, it is noteworthy that follow-up
studies clearly show that individual patients did not develop LV
dysfunction despite being pacemaker-dependent with 100% RV
pacing for years.11 The important role of individual factors possibly
conditioning a pre-disposition to the potentially deleterious effect
of RV pacing is historically stressed by the case of Arne Larsson,
the recipient of the first permanent cardiac pacemaker who
survived for 43 years with ventricular pacing systems (22 pulse
generators were implanted over the years) and died at the age of
86 without any major episode of heart failure.1
The observation that the occurrence of heart failure and CMP
in patients treated with permanent RV pacing for congenital
atrio-ventricular block and with a structurally normal heart is pre-
dicted by antinuclear antibodies, highlights how factors indepen-
dent of the pattern of ventricular electrical activation may play
a major role in the development of LV dysfunction after cardiac
pacing.14 In this complex interaction of factors, genetics can also
certainly play a major role, by determining an inherited predis-
position that will lead to a pattern of CMP and to overt heart
failure when exposure to risk factors for heart failure occurs.15
The incomplete knowledge of genotype–phenotype interactions
that characterizes our current approach to heart failure15 also
involves our attempts to explain the individual factors involved in
the appearance of a pattern of CMP after exposure to RV pacing
for variable periods of time. In this perspective, taking into account
the complexity of the pathophysiology and of the cause–effect rela-
tionship, it might be more cautious and appropriate to approach
this problem by considering this entity as a ‘pacing-associated’ CMP
rather than as a ‘pacing-induced’ CMP.
As shown in Figure 1, the electrical dyssynchrony that RV pac-
ing can induce at ventricular level is an important factor involved
in the pathophysiology of this form of CMP, but it does not fully ..
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.. explain per se the occurrence of LV dysfunction and heart failure,
since many factors can be involved in influencing and modulat-
ing the onset and progression over time of this syndrome. Fur-
ther, individual susceptibility and predisposition have an important
influence, due to variable factors whose impact is still not well
defined.
Different strategies for reducing and even avoiding the nega-
tive effects of RV apical pacing have been proposed, ranging from
algorithms to minimize unnecessary ventricular pacing, to alterna-
tive pacing sites, LV pacing, biventricular pacing, and more recently
His-bundle pacing.16,17 Although the benefits of cardiac resyn-
chronization therapy are well established in specific settings,18–20
the search for physiological pacing is currently characterized by
a growing interest in His-bundle pacing.9 In a new perspective
that takes into account the dynamic characteristics of a pattern
of dilated CMP,15 with LV remodelling as a target for treatments,
with important prognostic implications, it becomes important to
improve our knowledge on the determinants of partial or com-
plete regression of a CMP associated with long-standing RV api-
cal pacing in the case of upgrade to a more physiological pacing
modality.
Although strategies targeted to obtain more physiological pacing
modalities may play an important role for care improvement in
daily practice, with specific selection criteria that are still subject
of investigation, it is still necessary to better understand what
are the factors predisposing to the onset and worsening of LV
function in association with RV pacing, what are the links with the
complex pathophysiology of heart failure and what specific factors
can be actual aims of preventive or corrective interventions, with a
favourable risk–benefit profile, at specific phases of the ‘unnatural’
history of patients treated with cardiac pacing.
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